Brazil finally edges towards first drug pricing reform after two years – is it a missed opportunity?
In our recent blog on trends in international reference pricing (IRP), we mentioned that a public consultation...
Pricing and Market Access
Will IRP upend Czech orphan drug reforms?
On 14 September, the Czech Chamber of Deputies gave its final approval to the amendment...
Variations on an IRP theme: How payers are repurposing pricing policies for new categories of medicines
"Don't reinvent the wheel." "If it ain't broke, don't fix it." These are adages as...
Pharmaceutical and healthcare sectors jointly top global PMI ranking for first time
n an unusually pronounced trend, the IHS Markit Purchasing Managers Index (PMI)(tm) report for August...
Will physicians become more difficult to find in America?
The ability of the United States healthcare system to meet the needs of Americans has...
California’s Medicaid pharmacy “carve-out” set to boost state’s negotiating power, introduce IRP for drugs
California is planning a major overhaul of its Medicaid Pharmacy benefit, called Medi-Cal Rx, that will result in a "carve-out" of the entire pharmacy benefit from managed care to fee-for-service…
Trend towards HTA collaboration boosts need for data
The rising popularity of health technology assessments (HTAs) and similar framework agreements is presenting new challenges for the pharmaceutical industry. Several countries, including Ukraine, Moldova, Kazakhstan, and Saudi Arabia, are…
Barriers to market access for innovative medicines increase in the COVID era
The coronavirus disease 2019 (COVID-19) pandemic and governments responses are still impacting the pharmaceutical market globally, according to our latest market access risk scores (MARS). There was a temporary stabilization…
ESG permeates pharmaceutical pricing strategy
As ESG criteria gains greater traction across the pharmaceutical landscape, the push for pricing sustainability is growing more forceful. To be sure, drug pricing has always been tied to several…
Delta variant prompts change in policy responses
The B.1.617.2 variant of the COVID-19 virus, first identified in India in December 2020 and designated as the Delta variant of concern (VOC) by the World Health Organisation, has changed…
What the Aduhelm backlash may mean for pharma pricing in the ‘new normal’
The ongoing controversy over Biogen's Aduhelm treatment shows that pricing scrutiny has risen to a new level. The backlash after Biogen set the annual price for the drug at $56,000…
